4D Molecular Therapeutics (FDMT) Capital Expenditures Growth (1y) (2021 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 22,433.30% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -73.62% |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -100.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -100.77% |
| Mar 31, 2026 | -75.92% |
| Dec 31, 2025 | -120.23% |
| Sep 30, 2025 | -100.83% |
| Jun 30, 2025 | 153.46% |
| Mar 31, 2025 | 291.83% |
| Dec 31, 2024 | 72.86% |
| Sep 30, 2024 | 196.54% |
| Jun 30, 2024 | 15.03% |
| Mar 31, 2024 | -29.84% |
| Dec 31, 2023 | -49.77% |
| Sep 30, 2023 | -79.38% |
| Jun 30, 2023 | -61.04% |
| Mar 31, 2023 | -84.22% |
| Dec 31, 2022 | -78.55% |
| Sep 30, 2022 | -25.46% |
| Jun 30, 2022 | 180.33% |
| Mar 31, 2022 | 898.91% |
| Dec 31, 2021 | 944.26% |
| Sep 30, 2021 | 900.91% |